We are live on ! Find out more
1.52 USD
+0.09
6.29%
At close Updated Jul 31, 4:00 PM EDT
Pre-market
After hours
1.52
0.00
0%
1 day
6.29%
5 days
11.76%
1 month
-21.65%
3 months
-7.88%
6 months
22.58%
Year to date
14.29%
1 year
-74.71%
5 years
-99.9%
10 years
-99.85%
 

About: BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.

Employees: 13

0
Funds holding %
of 8,134 funds
Positive news %
Price charts implemented using Lightweight Charts™